Search

Research

Pulmonary exacerbations in cystic fibrosis are characterized by airway inflammation and may cause irreversible lung damage. Early identification of such exacerbations may facilitate early initiation of treatment, thereby potentially reducing long-term morbidity. Research question: Is it possible to predict pulmonary exacerbations in children with cystic fibrosis, using inflammatory markers obtained from BAL fluid?

Meet the AREST CF researchers

AREST CF has a detailed catalogue of our publications spanning back to 1996.

Development and validation of a miniaturized bacteriophage host range screening assay against antibiotic resistant Pseudomonas aeruginosa

Early disease surveillance in young children with cystic fibrosis: A qualitative analysis of parent experiences Sensitive measures of early lung

Cystic Fibrosis Clinical Isolates of Aspergillus fumigatus Induce Similar Muco-inflammatory Responses in Primary Airway Epithelial Cells

Ivacaftor and Airway Inflammation in Preschool Children with Cystic Fibrosis Authors: Paul McNally, Daryl Butler, Yuliya Karpievitch , Barry Linnane,

Development and validation of a miniaturized bacteriophage host range screening assay against antibiotic resistant Pseudomonas aeruginosa

Changes in airway inflammation with pseudomonas eradication in early cystic fibrosis Background: Neutrophil elastase is a significant risk factor for

BAL Inflammatory Markers Can Predict Pulmonary Exacerbations in Children With Cystic Fibrosis   Background: Pulmonary exacerbations in cystic